will be removed from its pipeline. In July, H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a buy rating ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB ... by the company’s clinical development and the rest of its pipeline assets, pointing to a higher view on the odds of success ...

AnaptysBio plans to release further data on rosnilimab and other pipeline assets in 2025, including studies for ulcerative colitis. These developments highlight AnaptysBio's ongoing efforts in ...

indicating expedited progress in the company's clinical development pipeline. AnaptysBio announced an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, which includes ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

They have a few legacy molecules that they are not actively pursuing in their pipeline. These are ANB032 and Imsidolimab. They keep running these through trials and then dropping them from the ...

AnaptysBio shares rose 7.2% on a share-repurchase program authorized to buy back up to $75 million of the company's common stock. Shares were recently trading around $18.31. The stock is down 15% ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...